Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02956278 · ClinicalTrials.gov registry record · Phase 4
The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics
A Phase 4 study of Hyperuricemia and Chronic Gout, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT02956278: Completed Phase 4 study of Hyperuricemia and Chronic Gout, sponsored by University of California, San Francisco.
NCT02956278 is a Phase 4 study of Hyperuricemia and Chronic Gout that has completed, run by University of California, San Francisco. The registered enrollment target is 27 participants, below the 162-participant average among 11 other Hyperuricemia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02956278, a Phase 4 study of Hyperuricemia and Chronic Gout, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.
Primary Outcome
Renal clearance as defined by amount excreted in 24 hours/AUC from 0-24 hours
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Allopurinol
Study Locations (1)
California
- Open Medicine Institute - Mountain View
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-11 |
| Est. Completion | 2018-03 |
| Phase | Phase 4 |
What the finished NCT02956278 record still lists
NCT02956278 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 162-participant average among 11 other Hyperuricemia trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Hyperuricemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02956278 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02956278 about?
NCT02956278 is a clinical study titled "The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics". Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.
What is the current status of trial NCT02956278?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2016-11. Estimated completion is 2018-03.
What conditions does trial NCT02956278 study?
This clinical trial studies the following conditions: Hyperuricemia, Chronic Gout.
What interventions are being tested in trial NCT02956278?
The interventions under investigation include: Placebo (OTHER), Allopurinol (DRUG).
Who is sponsoring clinical trial NCT02956278?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02956278 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperuricemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02956278's enrollment target sits among peer trials
27 7th of 11 higher than 5 of 11 other Hyperuricemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hyperuricemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
RECRUITING · Phase 2
-
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
ACTIVE NOT RECRUITING · Phase 3
-
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
ACTIVE NOT RECRUITING · Phase 1
-
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
ACTIVE NOT RECRUITING · Phase 3
-
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia